Farletuzumab-LNK4-S (DAR8)
Farletuzumab-LNK4-S (DAR8) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 8. Farletuzumab-LNK4-S (DAR8) is conjugated from the anti-FRα antibody Farletuzumab (HY-P99153) and LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR8) can be used in cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
FR-α |
Chemical Information
-
SMILES
[Farletuzumab-LNK4-S (DAR8)]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)